CADL vs CG: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CG is the larger of the two ($13.02B market cap): the incumbent the market prices for continued execution (7.60x forward earnings, beta 1.83). CADL is the smaller challenger ($400.47M), still expected to post a loss next year: more room to run, but more to prove. On the numbers, CG leads on both counts: faster expected revenue growth (25% vs 0%) and expected profits next year, which CADL does not have. The case for CADL rests on its own driver (The prostate cancer filing in mid-2027): if you believe in that, CADL fits; if you believe in what the numbers show today, CG does.

CADL vs CG: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCADLCGWhat it tells you
Market cap$400.47M$13.02BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-3.567.60Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta-0.291.83Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range8% of range4% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.042.60How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CADL and CG affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CADL and CG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CADL and CG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Candel Therapeutics (CADL) do?

Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. Its lead drug, aglatimagene besadenovec (CAN-2409), is an adenovirus carrying a gene that, paired with the oral antiviral valacyclovir, kills tumor cells and releases tumor antigens. A second platform uses a modified herpes virus, linoserpaturev (CAN-3110), now in a Phase 1b trial in recurrent high-grade glioma. Candel sells nothing yet, so every dollar of spending comes from equity and debt.

Full CADL guide

What does The Carlyle Group (CG) do?

Founded in 1987 and public since May 2012, Carlyle raises money from pension funds, sovereign wealth funds, insurers and, increasingly, individual investors, then deploys it across three reporting segments: Global Private Equity (buyouts, real assets, growth), Global Credit (direct lending, opportunistic credit, asset-backed finance, insurance solutions) and Carlyle AlpInvest (fund-of-funds, secondaries and co-investment, ~$112 billion of AUM on its own). About 2,500 employees work from 28 offices on four continents. Revenue arrives in three distinct shapes that behave nothing alike: recurring management fees charged on fee-earning capital, performance fees or carried interest recognised when funds exit investments above a hurdle, and principal investment income from the firm's own capital committed alongside clients. GAAP revenue therefore swings violently, from ~$3.0 billion in 2023 to ~$5.4 billion in 2024, which is why alternative managers report fee-related earnings and distributable earnings instead.

Full CG guide

CADL vs CG: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CADL drivers: The prostate cancer filing in mid-2027; Manufacturing readiness.
  • CG drivers: Fee-related earnings and the shift toward permanent capital; Credit and AlpInvest as second and third engines.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The main risk is regulatory. For CG, fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash.

CADL or CG: which should you pick?

If the story you believe is CADL's (The prostate cancer filing in mid-2027), CADL is the more direct way to own it; if it is CG's (Fee-related earnings and the shift toward permanent capital), CG is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CADL and CG guides.

CADL vs CG: the full fundamentals

CADL. With no sales, Candel is valued on its pipeline. At about $5.11 per share on November 20, 2026, the market cap is about $401M and enterprise value about $250M after netting ~$203M of cash against ~$50M of debt. That is the price the market puts on a drug with positive Phase 3 prostate data, a Phase 3 lung trial just started and an early glioma program. Analysts' average target was ~$22 before the delay and is about ~$17.67 across nine analysts after cuts from Stifel (to $19) and BofA (to $15), which shows how much of the gap depends on approval timing and dilution. A clean filing in mid-2027 or a further slip would likely move this valuation more than any quarterly loss figure.

CG. GAAP earnings and the multiples built on them are close to meaningless for this business in isolation, because principal investment marks and consolidated fund accounting dominate the reported line; trailing GAAP revenue of ~$2.8 billion is down even though fee-related earnings set a record and distributable earnings beat in both Q2 and Q3. The gap between a ~39 trailing multiple and a ~7.6 forward multiple is the market pricing in that distortion and, after a ~40% fall this year, a heavy discount for exit timing and rate risk. The mean target of the 19 analysts tracked by Yahoo Finance is ~$49 with a buy consensus, about a third above the November 20 price, down from ~$52.50 in October.

Headline figures (approximate, November 2026): CADL shows revenue (ttm) ~$0; no approved products, net loss ~$21.9M in Q3 2026 (EPS about -$0.28 vs ~-$0.31 expected); ~$69.6M for the first nine months, operating expenses ~$23.0M in Q3 2026, up from ~$13.2M a year earlier, cash (sept 30, 2026) ~$203M; runway guided into Q2 2028; CG shows total aum ~$485B as of June 30, 2026, up ~4% year over year, fee-related earnings (q2 2026) ~$358M, a record, up ~11% YoY at a ~47% margin, distributable eps (q3 2026) ~$1.12 vs ~$0.97 consensus (Q2: ~$1.07), gaap revenue / net income (ttm) ~$2.8B / ~$355M; Q3 GAAP revenue down ~19% YoY.

The bottom line: CADL vs CG

CADL and CG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CADL and CG exposure against your real portfolio. It is not an investment adviser.

Wondering how CADL or CG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Candel Therapeutics

Ask Walnut's AI anything about CADL and see how it fits what you own.

FAQ

What is the difference between CADL and CG?

+

Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. Founded in 1987 and public since May 2012, Carlyle raises money from pension funds, sovereign wealth funds, insurers and, increasingly, individual investors, then deploys it across three reporting segments: Global Private Equity (buyouts, real assets, growth), Global Credit (direct lending, opportunistic credit, asset-backed finance, insurance solutions) and Carlyle AlpInvest (fund-of-funds, secondaries and co-investment, ~$112 billion of AUM on its own). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CADL or CG the better stock?

+

Neither is universally better. CG is the larger incumbent; CADL is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CADL or CG?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CADL and CG?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CADL vs CG?

+

CADL: The main risk is regulatory. The BLA has already moved once, from late 2026 to mid-2027, and the company says the timing still depends on FDA discussions, so another delay is possible. The FDA could also question the trial's endpoint, the size of the benefit, or the comparison with current care, which in intermediate-risk patients often adds short-course hormone therapy to radiation. Manufacturing is a second risk: viral gene therapies have drawn FDA complete response letters over CMC issues, and assay work is the cause of the current delay. Financing is a third. Cash lasts into Q2 2028, about when an approval could come, so a further slip probably means raising money at a depressed share price; the Trinity loan's later tranches depend on milestones. Lung cancer is a fourth: AURORA is a large, costly trial and a Phase 2a survival figure from a single-arm study often shrinks in randomized testing. Short interest was ~17% of shares outstanding before the drop, which can make the stock move sharply in both directions. With no revenue, the share price has no earnings floor. CG: Fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. Performance fees are inherently lumpy and unrealised carry is a mark, not money, meaning distributable earnings can fall by half in a quiet quarter without anything fundamental breaking. Higher-for-longer rates raise financing costs across portfolio companies and compress private-market valuations, while heavy competition for direct lending assets pressures credit spreads. On the legal side, a Delaware fiduciary-duty suit brought by a pension fund against co-founders William Conway, Daniel D'Aniello and David Rubenstein and other directors over a ~$344 million payment to terminate the firm's tax receivable agreement was allowed to proceed in 2024 and remains a derivative matter rather than a securities-fraud class action; no active securities-fraud class action against Carlyle was identified as of November 2026. Regulators in the US and Europe continue to scrutinise fee disclosure, valuation practices and the push of illiquid strategies into retail and retirement channels, which is precisely where much of the growth plan sits. Large transactions can also slip away: Carlyle stepped back from the Lukoil international asset purchase in October 2026, months after agreeing to it, which shows how sanctions and politics can redirect deployment plans. The share price shows how heavily these risks weigh: CG fell ~25% in the three months to November 20, 2026 despite two straight quarters of earnings beats.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CADL or CG; figures are approximate and dated (as of November 2026). Verify current data before investing.